Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
October 07 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Suber S. Huang, MD, MBA,
FASRS, Co-Founder and CEO of the Retina Center of Ohio, will
present data from Outlook Therapeutics’ NORSE THREE supplemental
safety study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an
investigational ophthalmic formulation of bevacizumab for use in
retinal indications. Dr. Huang’s oral presentation will take place
at the 2021 Annual Meeting of the American Society of Retina
Specialists being held in San Antonio, Texas.
Details for the presentation are as follows:
Safety Results of ONS-5010, an
Ophthalmic Bevacizumab, in Treated Eyes of Patients with Wet AMD,
DME and BRVOPresenter: Suber S. Huang, MD, MBA, FASRSDate
and time: October 12, 2021, at 11:08-11:14 AM CDT
For more information and to register for this
event, please visit https://www.asrs.org/annual-meeting.
About the American Society of Retina
Specialists
The American Society of Retina Specialists is
the largest organization of retina specialists in the world,
representing over 3,000 physicians in all 50 US states, the
District of Columbia, Puerto Rico, and 63 countries. The Society
serves as a national advocate and primary source of clinical and
scientific information and education for its members.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024